mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars.
The project represents a pioneering step in the application of AI to industrial biotechnology through the creation of a digital twin of the biological process, designed to enhance predictability, consistency, and efficiency in large-scale production.“This is a clear example of technology with purpose: we use artificial intelligence not only to optimize processes but to help critical treatments reach more people, faster and better,” said Sergio Martínez, Technical Lead of the project at HP.
Beyond its technological innovation, this solution holds transformational potential for all of mAbxience’s partners, both biosimilar licensees and CDMO clients. By integrating AI into its manufacturing operations, mAbxience aims to significantly optimize its development approach towards biologics development, enhancing operational efficiencies, and optimizing resource utilization. This advancement will strengthen the company’s position as a trusted, cost-competitive global biomanufacturing partner, while helping to optimize patient access to safe, high-quality biologic medicines.
“Artificial intelligence may open a lot of yet untapped potential for biomanufacturing optimization,” said Timo Liebig, Chief Innovation Officer at mAbxience.
“Through this collaboration with HP, we have successfully developed our first prototype enabling more efficient, more robust and even more tightly controlled manufacturing campaigns. This project demonstrates how technological innovation can directly translate into better access for patients to essential biologic therapies,” commented Iván Sánchez, R&D Director at mAbxience.
The development was based on real production data processed through advanced neural network models and validated in an industrial setting. The resulting tool allows mAbxience teams to simulate, analyze, and optimize distinct stages of the cell culture manufacturing process, with the ultimate goal of increasing yields while reducing process variability.
This initiative marks the first project under the strategic collaboration framework between HP and mAbxience, which aims to apply AI across multiple critical areas of the company to enhance productivity, quality, and sustainability throughout its global operations. The solution, designed and validated in León, also has potential to be replicated across other mAbxience sites and processes worldwide. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
This project has been co-financed with public funds by the Institute for Business Competitiveness of Castilla y León (ICECYL), the Regional Government of Castilla y León, and the European Union, through the European Regional Development Fund (ERDF). More information on co-financed projects: https://mabxience.com/funded-projects/
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.
